94 results about "Subunit vaccines" patented technology

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The invention discloses a chicken infectious anemia subunit vaccine composition as well as a preparation method and application thereof. The vaccine composition contains a mixture of CIAV (Chicken Infectious Anemia Virus) VP1 and VP2 proteins, the mixture of the VP1 and VP2 proteins is prepared by performing in-vitro renaturation on VP1 inclusion body proteins by using a gradient dialysis method, adding pre-purified VP2 proteins in the dialysis process to promote the recovery of key conformation epitopes of the VP1 proteins, and then gradually removing a denaturing agent to obtain the VP1 and VP2 protein mixture. And refolding the VP1 protein to obtain the protein. The soluble VP2 protein is used as a molecular chaperone to recover the VP1 protein from the inclusion body. According to the VP2 protein assisted synergistic refolding strategy, the key conformation epitope of the VP1 protein is recovered by using the natural function of the VP2 protein. Subsequently, the immunogenicity and protective efficacy of the refolded VP1 and VP2 protein mixture are evaluated, and an economic and effective technical means is provided for preventing and controlling chicken infectious anemia.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present disclosure belongs to the field of biotechnology, and specifically relates to a seven-component antigen African swine fever subunit vaccine. The present disclosure first provides an African swine fever virus antigen protein combination composed of the African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, C129R protein, X protein, and Y protein. This African swine fever virus antigen protein combination can induce a strong immune response in the host. Furthermore, the present disclosure provides a seven-component antigen African swine fever subunit vaccine including the aforementioned African swine fever virus antigen protein combination. The seven-component antigen African swine fever subunit vaccine exhibits good immunoprotection rates against challenge with the parental virulent African swine fever virus strain, poses no biosafety risks, overcomes the difficulty that existing African swine fever subunit vaccines domestically and internationally cannot provide effective immunoprotection for pigs.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention discloses a recombinant duck plague virus protein combination, a subunit vaccine as well as a preparation method and application of the subunit vaccine, and belongs to the technical field of vaccine preparation. According to the technical scheme, the recombinant duck plague virus protein combination comprises recombinant gE protein and recombinant gI protein; the amino acid sequence of the recombinant gE protein is as shown in SEQ ID NO: 10, and the amino acid sequence of the recombinant gI protein is as shown in SEQ ID NO: 13. The nucleotide sequence of the nucleic acid molecule for coding the recombinant gE protein is as shown in SEQ ID NO: 12; the nucleotide sequence of the nucleic acid molecule for coding the recombinant gI protein is as shown in SEQ ID NO: 15. The duck plague subunit vaccine provided by the invention adopts gE and gI co-expression, only contains part of antigens of DPV, does not contain genetic materials, does not have toxin expelling and dispersing risks, is good in safety, can enable the spatial conformation of gE protein to be close to that of natural protein by co-expression of gE and gI, can realize 10 / 10 protection of challenge, has the total protein expression amount of about 4000 [mu] g / ml, and can be used for preparing a vaccine for the duck plague. The culture medium can be diluted by 40 times for seedling production, so that the production cost is greatly reduced.

The invention discloses a fusion protein and application thereof. Belongs to the technical field of biological medicine. The invention provides a novel fusion molecular architecture which comprises fusion proteins coded by wza and hphA genes and can be used for research and development of nucleic acid vaccines or subunit vaccines. The invention finds that the new fusion molecule has good expression and secretion ability and immunogenicity, can provide effective immune protection effect, and significantly inhibits acinetobacter baumannii infection and colonization. The invention also provides corresponding recombinant nucleic acid, a gene expression cassette, a vector, a host cell, a pharmaceutical composition, a vaccine, application and the like.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a swine fever-porcine pseudorabies bivalent subunit vaccine containing a traditional Chinese medicine immunopotentiator as well as a preparation method and application of the swine fever-porcine pseudorabies bivalent subunit vaccine. The enhancer is prepared by compounding a hypericum perforatum extract and a horse chestnut seed extract, the hypericum perforatum extract and the horse chestnut seed extract are mixed with a classical swine fever virus (CSFV) E2 protein, a pseudorabies virus (PRV) gB protein, a PRV gD protein and an adjuvant to prepare a subunit vaccine, the vaccine can remarkably improve the humoral immunity level and the cellular immunity level excited by the vaccine at the same time, and the vaccine can be used for preparing the vaccine. Specifically, cell factors such as neutralizing antibodies GMT and IFN-gamma are remarkably increased, and the uniformity and stability of immune response are promoted, so that the immunogenicity of the existing swine fever-porcine pseudorabies bigeminy subunit vaccine is effectively improved, and the protection effect of the vaccine is enhanced.

The invention belongs to the technical field of genetically engineered bacteria, and particularly discloses an African swine fever oral vaccine saccharomyces cerevisiae engineered bacterium as well as a construction method and application thereof. A free plasmid system is adopted to transform saccharomyces cerevisiae, and an engineering strain for displaying ASFV p30 / p54 antigens is constructed. The matched plasmid system has the advantages of being simple and convenient to operate and short in construction period, construction and transformation of recombinant plasmids can be completed in a short time, and the research and development efficiency of vaccine candidate strains is remarkably improved. Meanwhile, the free plasmid can be stably inherited and copied in a yeast host, so that the expression stability of a target antigen in a passage process is guaranteed, and large-scale fermentation preparation is facilitated. After oral immunization, the saccharomyces cerevisiae engineering bacterium constructs a system-mucous membrane dual defense barrier in a tested animal pig body, not only induces high-level system IgG, but also induces remarkable sIgA mucous membrane immunity in intestinal tracts, and provides a new idea and technical reserve for research and development of ASFV subunit vaccines.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

The application discloses a broad-spectrum protective antigen of avian pathogenic bacterium and application thereof, and belongs to the field of poultry infectious disease prevention and control. The application provides application of avian pathogenic bacterium protein p1 in preparation of a broad-spectrum protective antigen protein of avian pathogenic bacterium, and the amino acid sequence of the avian pathogenic bacterium protein p1 is shown as SEQ ID No. 1. The protective antigen protein has strong immunogenicity and reactivity, and a subunit vaccine prepared by using the antigen protein can provide 90% protection rate of chickens to A, B and C three serotypes of avian pathogenic bacterium, and can effectively prevent infection of the avian pathogenic bacterium.

The invention provides a bivalent bovine viral diarrhea virus antigen protein composition, a subunit vaccine as well as a preparation method and application of the bivalent bovine viral diarrhea virus antigen protein composition and the subunit vaccine, and belongs to the technical field of genetic engineering vaccines. The bivalent bovine viral diarrhea virus antigen protein composition is prepared from a recombinant protein kozak-MLTsp-BVDV1-E2-His and a recombinant protein kozak-IgKsp-BVDV2-E2-His, the amino acid sequence of the recombinant protein kozak-MLTsp-BVDV1-E2-His is as shown in SEQ ID NO.16, and the amino acid sequence of the recombinant protein kozak-IgKsp-BVDV2-E2-His is as shown in SEQ ID NO.18. The invention further discloses a preparation method of the bivalent bovine viral diarrhea virus antigen protein composition. According to the invention, efficient expression of BVDV-1 and BVDV-2 E2 proteins is realized, high-purity E2 proteins are obtained, the safety and effectiveness of vaccines are ensured, and the antibody level of the vaccines is improved.

The invention relates to the technical field of biology, in particular to a porcine rotavirus and porcine epidemic diarrhea virus bivalent subunit vaccine and application thereof, and the active ingredient of the vaccine is an antigen protein combination composed of VP4, VP7 and S1 protein. The three proteins have a synergistic enhancement effect during combined immunization, and the S1 protein can cooperate with VP4 and VP7 antigens to significantly improve the early humoral immune response level. Besides, the antigen combination can induce an organism to generate high-level specific antibodies and virus neutralizing antibodies and stimulate remarkable cellular immune response, and has good application potential in the aspect of combined prevention and control of the porcine rotavirus and the porcine epidemic diarrhea virus.

This invention discloses a chimeric spike protein of PEDV and TGEV, a bivalent subunit vaccine, its preparation method, and its applications, relating to the field of biotechnology. The amino acid sequence of the spike protein chimera is shown in SEQ ID NO.13. This invention disrupts the formation of the secondary structure of the TGEV S protein by mutating it, maintaining the pre-fusion conformation of the S protein. Furthermore, while maintaining the pre-fusion trimer conformation of TGEV S, the DO-NTD region of TGEV S is replaced with the DO-NTD region of PEDV S, thus obtaining a spike protein chimera. Immunization using this spike protein chimera can generate neutralizing antibodies against both PEDV and TGEV, providing simultaneous prevention and control of both PEDV and TGEV.

The application discloses application of an ABC transporter substrate-binding protein in preparation of an anti-Fusobacterium nucleatum vaccine and belongs to the technical field of biotechnology.The ABC transporter substrate-binding protein (ABC-sbp) is a rnlrABC-sbp without a leading region which is expressed by an E. coli expression system, and the amino acid sequence of the rnlrABC-sbp is shown as SEQ ID NO. 2. In addition, the application further discloses a genetic engineering subunit vaccine against the Fusobacterium nucleatum, which comprises the rnlrABC-sbp protein with the amino acid sequence shown as SEQ ID NO. 2 and an adjuvant. The genetic engineering subunit vaccine against the Fusobacterium nucleatum prepared by using the rnlrABC-sbp protein can stimulate the body to produce a large amount of antibodies, resist the attack of the Fusobacterium nucleatum, reduce the damage of the body and improve the survival rate, and has important application value in the field of prevention and treatment of the Fusobacterium nucleatum infection.

The application provides an avian PCV3 gene and application thereof, and belongs to the technical field of animal virology and immunology. The application provides an avian PCV3 gene for the first time, which is named aPCV3, and the nucleotide sequence of the aPCV3 gene comprises any one of SEQ ID NO. 1-2 or a sequence with a homology of more than 90% with SEQ ID NO. 1 and 2. The virus strain containing the aPCV3 gene has a high virus titer and can be stably passaged for multiple times. The inactivated vaccine prepared from the virus strain containing the aPCV3 gene and the subunit vaccine prepared from the Cap gene or the Rep gene in the aPCV3 gene have a significant protective effect on poultry such as chickens, ducks and geese. The ELISA detection plate prepared from the Cap gene or the Rep gene in the aPCV3 gene can accurately detect PCV3 and has high specificity and repeatability.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The invention relates to the technical field of biology, and discloses a recombinant protein VP2-Cap as well as a preparation method and a vaccine thereof. According to the present invention, the GoCV Cap gene segment and the GPV VP2 gene segment are successfully amplified, the fusion gene VP2-Cap segment is obtained, and the recombinant plasmid pET-28a-VP2-Cap is constructed and successfully expressed so as to obtain the recombinant protein VP2-Cap; the recombinant protein VP2-Cap is soluble and efficient in expression in an escherichia coli system, the problems of complex process and activity loss of inclusion body renaturation are avoided, and the recombinant protein VP2-Cap is high in activity and is an ideal antigen for preparing efficient subunit vaccines.

The present disclosure belongs to the field of biotechnology, and specifically relates to a nine-component antigen African swine fever subunit vaccine. The present disclosure first provides an African swine fever virus antigen protein combination composed of the African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, E165R protein, C129R protein, P72 protein, X protein, and Y protein. This African swine fever virus antigen protein combination can induce a strong immune response in the host. Furthermore, the present disclosure provides a nine-component antigen African swine fever subunit vaccine including the aforementioned African swine fever virus antigen protein combination. The nine-component antigen African swine fever subunit vaccine exhibits good immunoprotection rates against challenge with the parental virulent African swine fever virus strain, poses no biosafety risks, overcomes the difficulty that existing African swine fever subunit vaccines domestically and internationally cannot provide effective immunoprotection for pigs.

The invention provides an application of a mycobacterium tuberculosis antigen Rv1471 in preparation of drugs or vaccines for preventing and / or treating diseases caused by mycobacterium infection. In a cell model, the antigen Rv1471 can promote the maturation of phenotypes and functions of macrophages, and also can mediate training immunity. On the basis, a subunit protein vaccine for expressing the antigen Rv1471 is further constructed. In a mouse immune model, the immunogenicity of the subunit protein vaccine expressing the antigen Rv1471 in a mouse which is not immunized by BCG is measured, and the subunit protein vaccine can promote antigen-specific T cell immune response. In a cell model and an acute infection mouse model, the antigen Rv1471 can provide an effective protection effect against mycobacterium tuberculosis infection. Therefore, the antigen Rv1471 and the subunit vaccine thereof are expected to become a novel preventive / therapeutic tuberculosis vaccine.

This invention discloses a combination of *Haemaphysema contortus* antigen proteins and its application in the preparation of a protective subunit vaccine against *Haemaphysema contortus*, belonging to the field of veterinary vaccines. The subunit vaccine of this invention comprises galactose and fucose-modified antigen proteins MEP1, MEP3, MEP4, PEP2, and CP1. The fucose modification includes proximal and distal α1,3-fucose modification. The antigen proteins in this subunit vaccine are closer to the natural proteins in terms of N-glycosylation modification, and can induce protective antibodies in goats after mixed immunization, significantly reducing the number of *Haemaphysema contortus* parasites and the number of eggs laid by the parasites. The subunit vaccine of this invention can be used to prepare drugs for the prevention and treatment of *Haemaphysema contortus* disease. This invention lays the foundation for the development of *Haemaphysema contortus* subunit vaccines, provides an effective technical means for the prevention and treatment of this disease, and has significant application value and promising prospects for promotion.

The application discloses a Gitta virus genetically engineered subunit vaccine and a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The Gitta virus P6E recombinant protein is obtained by using a eukaryotic expression system, and is further loaded on the surface of a nanoparticle skeleton to form a recombinant nanoparticle. The obtained recombinant protein and the recombinant nanoparticle are respectively compounded with an adjuvant to prepare the genetically engineered subunit vaccine. After twice immunization, the vaccines of the two components can significantly induce the host to produce strong humoral immune and cellular immune responses, thereby providing effective protection against GETV infection. The technical scheme of the application provides an important technical basis and application reference for research and optimization of the Gitta virus vaccine.

This invention relates to the field of microbiology, specifically to a high-ApxI toxin-producing APP strain, its construction method, and its applications. This invention provides a strain of *Actinobacillus pleuropneumoniae*, with the accession number CGMCC No. 25495. The *Actinobacillus pleuropneumoniae* exhibits an ApxI toxin yield as high as 2.367 ± 0.25 mg / L, more than three times that of the wild-type strain. This invention provides a new approach and method for constructing high-ApxI toxin-producing strains, offering a new strain resource for the production of *Actinobacillus pleuropneumoniae* subunit vaccines.

This invention discloses a bivalent subunit vaccine against Echinococcus granulosus and Echinococcus cantonensis, and its preparation method. The bivalent subunit vaccine comprises the immunogen dEG95 / dEC95 antigen protein and a pharmaceutically acceptable carrier. The amino acid sequence of the dEG95 protein is shown in SEQ ID No. 1, and the amino acid sequence of the dEC95 protein is shown in SEQ ID No. 2. Currently, there are no vaccines that simultaneously protect against Echinococcus granulosus and Echinococcus cantonensis infection. This invention uses the dEG95-dEC95 heterodimeric protein as the antigen, and the prepared bivalent subunit vaccine against both Echinococcus granulosus and Echinococcus cantonensis has low production cost and a simple production process. It can simultaneously prevent infection by both Echinococcus granulosus and Echinococcus cantonensis, and has many advantages such as safety, high efficiency, low cost, and high antigen purity.

This invention relates to the field of Clostridium perfringens antigen technology, and particularly to a Clostridium perfringens α-toxin-ferritin nanoparticle antigen, its preparation method, and its application. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen is assembled from αm2ST protein and FeSC protein. The αm2ST protein is expressed using an α-protein mutant expression plasmid, and the FeSC protein is expressed using a ferritin expression plasmid. The nucleotide sequence of the α-protein mutant expression plasmid is shown in SEQ ID NO: 1, and the nucleotide sequence of the ferritin expression plasmid is shown in SEQ ID NO: 2. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen provided by this invention can effectively stimulate humoral and cellular immunity, providing a new approach for the development of Clostridium perfringens subunit vaccines.

The application provides a method for diagnosing and differentiating classical swine fever based on a classical swine fever E2 subunit vaccine, which comprises the following steps: immunizing pigs in a pig farm with the classical swine fever E2 subunit vaccine, detecting E0 antibodies and E2 antibodies after one year of immunization, and eliminating the pigs with E0 antibodies until both the E0 antibodies and the CSFV nucleic acid detection are negative, which indicates that the classical swine fever is purified. The classical swine fever E2 subunit vaccine comprises a nucleic acid fragment encoding an antigen protein with the amino acid sequence of SEQ ID NO: 5 inserted into a recombinant expression vector. The classical swine fever E2 subunit vaccine provided by the application has good immunoprotective efficacy on pigs, and a classical swine fever epidemic disease purification method is established by using the subunit vaccine. The application effect of the method in a pig breeding company for two years shows that the method can effectively purify the classical swine fever, which indicates that the purification method provided by the application is feasible and can be popularized and applied.